Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck restructuring Programs — Total Ending Accrual Reserve ($M) ($M)
Form 10-Q / 10-K Restructuring Footnote
Latest, Q1 2025
557
Period ended Mar 31, 2025
Change on a year earlier
-24.3%
736 in Q1 2024
History
31 quarters
Since Q4 2016
Sources
28
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring Programs — Total Ending Accrual Reserve ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2025 | Mar 31, 2025 | 557 | -24.3% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 564 | -20.8% | Form 10-Q (filed 2025-05-02) ↗ |
| Q3 2024 | Sep 30, 2024 | 651 | +14.8% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 687 | +19.1% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 736 | +45.5% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 712 | +38.8% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2023 | Sep 30, 2023 | 567 | +8.8% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 577 | -1.9% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 506 | -13.2% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 513 | -19.5% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2022 | Sep 30, 2022 | 521 | -14.9% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 588 | -12.4% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 583 | -18.2% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 637 | +8.7% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2021 | Sep 30, 2021 | 612 | +28.0% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2021 | Jun 30, 2021 | 671 | +35.8% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2021 | Mar 31, 2021 | 713 | +13.9% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 586 | -18.0% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2020 | Sep 30, 2020 | 478 | -28.3% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 494 | -9.0% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 626 | +7.4% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 715 | +33.9% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 667 | +16.4% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 543 | -8.0% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 583 | -10.4% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 534 | -28.5% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 573 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 590 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 651 | – | Form 10-Q (filed 2018-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 747 | +38.1% | Form 10-K (filed 2020-02-26) ↗ |
| Q4 2016 | Dec 31, 2016 | 541 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). Merck Restructuring Programs — Total Ending Accrual Reserve ($M) ($M), quarterly Q4 2016–Q1 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr_total_reserve
See every metric in the Merck KPI table. Data updated Oct 26, 2026.